WHAT WE DO
Novel, orally available immune modulator MP1032 with anti-SARS-CoV-2 and anti-cytokine activity (iMPact)
The iMPact project aims to demonstrate that the asset MP1032 is a promising new candidate for the early intervention treatment of COVID-19 patients. MP1032 is a first-in-class drug candidate that reduces inflammatory markers such as TNF-alpha, IL-6, IL-12. These anti-inflammatory properties make it a highly promising compound for early intervention treatment of COVID-19.
MP1032 has a dual mode of action, combining anti-viral activity with immune modulation:
- It reduces oxidative stress: oxidative stress is a core driver of the immune over-activation in severe COVID-19
- It blocks viral replication: oxidative stress also facilitates replication of SARS-CoV-2 in infected cells and the host-mediated drug target can therefore be used to inhibit viral replication.
MP1032 is the first effective immunomodulator that targets oxidative stress, while maintaining normal cellular functions. It has already been proven to be safe, economical, easy to distribute & administer.
WHO WE ARE
Partner Organisations
OUR NUMBERS
Let's talk figures
iMPact began in August 2021 and will run until February 2023.
18
Months
7,9
Million
3
Countries
6
Work Packages
33
Deliverables
